Phase II Study of Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).

  • STATUS
    Recruiting
  • End date
    Dec 31, 2025
  • participants needed
    30
  • sponsor
    National Cancer Institute (NCI)
Send
Updated on 24 October 2022
See if I qualify
cancer
measurable disease
KRAS
hydroxychloroquine
EGFR

Summary

Background

Bile duct cancer is cancer of the slender tubes of the biliary tract. These tubes carry bile through the liver. Such cancer tumors often have an abnormal or mutated gene. Researchers think a mix of drugs can slow the progression of gene-mutated cancers of the biliary tract.

Objective

To see if using a combination of trametinib and hydroxychloroquine (HCQ) increases the period of time it takes for a person s bile tract carcinoma (BTC) to get worse.

Eligibility

Adults age 18 and older with BTC.

Design

Participants will be screened with a physical exam, medical history, and cancer history. Their ability to do their normal activities will be assessed. They will have blood and urine tests. They will give a tumor sample. They will have heart tests. They may talk with a heart doctor. They may have an eye exam. They may have a tuberculosis test. They will have computer tomography (CT) scans of the chest, abdomen, and pelvis. They may have magnetic resonance imaging (MRI) scans of the chest, abdomen, pelvis.

Participants will repeat some screening tests throughout the study.

Participants will take HCQ and trametinib tablets by mouth daily in 28-day cycles. They will have study visits once a month. They will take the drugs until they have bad side effects or the drugs stop working.

Participants will have one more tumor biopsies during the treatment. They will have blood taken often.

One month after treatment ends, participants will have a safety follow-up visit. Then they will be called or emailed every 6 months for the rest of their life....

Description

Background
  • Among the new cases of bile tract carcinoma (BTC) that are diagnosed every year in the United States, there are approximately 6,500 cases of gallbladder carcinoma, 3,000 cases of extrahepatic cholangiocarcinoma, and 3,000 cases of intrahepatic cholangiocarcinoma.
  • Current treatment options for patients with cholangiocarcinoma are limited and take no account of the known biological and genetic heterogeneity in these diseases. Median survival for advanced disease remains poor at approximately 1 year.
  • Activating KRAS mutations are frequently detected in all subtypes of BTC and can be found in up to 40% of BTC, predominantly in perihilar and distal cholangiocarcinoma (CCA). However, pharmacological inhibition of mutated KRAS has demonstrated little clinical benefit in general.
  • Trametinib is a reversible, highly selective allosteric inhibitor of mitogen-activated extracellular signal regulated kinases MEK1 and MEK2. Tumor cells with KRAS mutations commonly have hyperactivated extracellular signal-related kinase (ERK) pathways in which activated MEK is a critical component. However, tumors are able to overcome MEK signaling inhibition by trametinib through upregulation of autophagy pathway.
  • Hydroxychloroquine (HCQ) inhibits lysosomal acidification and prevents the degradation of autophagosomes, to suppress autophagy.
  • Trametinib has been approved by FDA for the treatment of melanoma as a single agent or for the treatment of other cancers if tumors carry BRAF mutation. Hydroxychloroquine are approved for the treatment of malaria, lupus erythematosus and acute or chronic rheumatoid arthritis.
  • Preclinical studies have shown that combined treatment of trametinib plus HCQ elicited striking tumor regression in animal model.
    Objective

-To determine whether the 5-month progression free survival (PFS) of the trametinib plus hydroxychloroquine (HCQ) combination in subjects with refractory bile tract carcinoma (BTC) with KRAS mutation exceeds 25%.

Eligibility
  • Histopathological confirmation of BTC or carcinoma highly suggestive of a diagnosis of BTC.
  • Tumor must have KRAS mutation.
  • Patients must have disease that is not amenable to potentially curative resection, transplantation or ablation.
  • Age greater than or equal to 18 years
  • Patients must have measurable lesion by RECIST 1.1.
  • At least two weeks washout period from previous therapy
  • ECOG less than or equal to 2
  • Adequate renal, hepatic and bone marrow function
Design

-The study is open-labeled phase 2 study. It is designed to enroll total 30 patients with refractory BTC, to test the hypothesis that treatment with a combination of HCQ and trametinib prevents cancer progression/recurrence. We propose that this combination will have relative safety profile and antitumor efficacy in BTC patients with KRAS mutation.

Details
Condition Bile Duct Cancer, Biliary Cancer, Biliary Tract Neoplasms, Cholangiocarcinoma
Treatment hydroxychloroquine, Trametinib
Clinical Study IdentifierNCT04566133
SponsorNational Cancer Institute (NCI)
Last Modified on24 October 2022

Eligibility

 Yes No Not Sure

Inclusion Criteria

Histopathological confirmation of
biliary tract carcinoma (BTC) OR carcinoma in the setting of clinical and radiological characteristics which, together with the pathology, are highly suggestive of a diagnosis of BTC
Note: The term BTC includes intra- or extra- hepatic cholangiocarcinoma (CCA), gallbladder
cancer or ampullary cancer
The tumor must have KRAS mutation(s) of clinical significance, confirmed by NCI
Patients must have received or been intolerant of at least one line of chemotherapy
Laboratory of Pathology or by FDA approved test
Patients must have at least 1 measurable lesion by RECIST version 1.1
Age greater than or equal to 18 years
Patients must have disease that is not amenable to potentially curative resection
Performance status (ECOG) 0-2
ablation or transplantation
If liver cirrhosis is present, patient must have a Child-Pugh score <7 (Class A)
Patients must have adequate organ and marrow function as defined below
ANC greater than or equal to 1,500/mcL
platelets greater than or equal to 100,000/mcL
hemoglobin greater than or equal to 9 g/dL
ALT or AST less than or equal to 5 x ULN
total bilirubin if cirrhosis present: Part of Child Pugh requirement. If no
Notes
cirrhosis: bilirubin should be less than or equal to 1.5 x ULN
ALT (SGPT)=alanine aminotransferase (serum glutamic pyruvic transaminase)
Creatinine OR Measured or calculated creatinine clearance (CrCl) (eGFR may also
be used in place of CrCl) : < 1.5x institution upper limit of normal OR
GFR=glomerular filtration rate; ULN=upper limit of normal
greater than or equal to 30 mL/min/1.73 m^2 for participant with creatinine
levels greater than or equal to 1.5 X institutional ULN
AST (SGOT)=aspartate aminotransferase (serum glutamic oxaloacetic transaminase)
Patients must be able to understand and be willing to sign a written informed consent
Creatinine clearance (CrCl) or eGFR should be calculated per institutional standard
Patients must have at least 1 focus of disease that is amenable to mandatory tumor
biopsies and be willing to undergo this. Ideally, the biopsied lesion should not be
one of the target measurable lesions, although this can be up to the discretion of the
investigators
The study drugs are harmful for developing human fetus. For this reason, women of
childbearing potential and men must agree to use adequate contraception (hormonal or
barrier method of birth control; abstinence) at the study entry, for the duration of
study treatment and up to 4 months after the last dose of the study drug(s). Should a
woman become pregnant or suspect she is pregnant while she or her partner is
participating in this study, she should inform her treating physician immediately

Exclusion Criteria

History of glucose-6-phosphate dehydrogenase (G6PD) deficiency
History of seizures
Patients who have had standard-of-care anti-cancer therapy within 2 weeks of treatment
initiation or therapy with investigational agents (e.g. chemotherapy, immunotherapy
Screening corrected QT interval by Fridericia's (QTcF) > 500 msec
endocrine therapy, targeted therapy, biologic therapy, tumor embolization, monoclonal
antibodies or other investigation agents), large field radiotherapy, or major surgery
within 4 weeks of treatment initiation
Any unresolved toxicity NCI CTCAE v.5 Grade greater than or equal to 2 from previous
anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values
defined in the inclusion criteria. Patients with Grade greater than or equal to 2
neuropathy will be evaluated on a case-by-case basis
Has biliary duct obstruction, unless a treatable, clinically relevant obstruction has
been relieved by internal endoscopic drainage/stenting, palliative by-pass surgery or
percutaneous drainage prior to treatment initiation
Patients with known brain metastases are excluded from this clinical trial because of
their poor prognosis and because they often develop progressive neurologic dysfunction
that would confound the evaluation of neurologic and other adverse events
Patients with signs of liver failure, e.g. clinically significant ascites
encephalopathy, or variceal bleeding within six months before treatment initiation
History or current evidence of retinal vein occlusion (RVO) or current risk factors
for RVO (e.g. uncontrolled glaucoma or ocular hypertension, history of hyper viscosity
or hypercoagulability syndromes)
Current evidence of uncontrolled, significant intercurrent illness including, but not
limited to, the following conditions
Cardiovascular disorders: Congestive heart failure New York Heart Association
class 3 or 4, unstable angina pectoris, serious cardiac arrhythmias, stroke
(including transient ischemic attack [TIA]), myocardial infarction (MI), or other
ischemic event, or thromboembolic event (e.g., deep venous thrombosis, pulmonary
embolism) within 3 months before treatment initiation
Patients who are planning on embarking on a new strenuous exercise regimen after
first dose of study treatment. Muscular activities, such as strenuous exercise
that can result in significant increases in plasma creatine kinase (CK) levels
should be avoided while on study treatment
Patients who have neuromuscular disorders that are associated with elevated CK
(e.g., inflammatory myopathies, muscular dystrophy, amyotrophic lateral
sclerosis, spinal muscular atrophy)
Impairment of gastrointestinal function or gastrointestinal disease (e.g
ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption
syndrome, or small bowel resection that under the judgment of the principal
investigator (PI) may impair absorption of study drugs)
Any other condition that would, in the Investigator s judgment, contraindicate
the patient s participation in the clinical study due to safety concerns or
compliance with clinical study procedures, e.g., infection/inflammation
intestinal obstruction, unable to swallow medication (patients may not receive
drug through a feeding tube), social/psychological issues, etc
Known infection with human immunodeficiency virus (HIV), unless patient is on
effective anti-retroviral therapy with undetectable viral load within 6 months of
treatment initiation
Known chronic hepatitis B virus, unless hepatitis B virus (HBV) viral load is
undetectable
Known history of hepatitis C virus (HCV) infection, unless completed treatment and
cured with undetectable HCV viral load
Known prior severe hypersensitivity to study drugs or any component in its
formulations (CTCAE v5.0 grade >= 3)
Pregnant women are excluded from this study because study therapy can cause fetal
harm. Because there is potential risk for adverse events in nursing infants secondary
to treatment of the mother with study therapy, breastfeeding should be discontinued if
the mother is treated with study drugs
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

cancer
measurable disease
KRAS
hydroxychloroquine
EGFR

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note